BPC 157 Dosage: What the Research Reported

Medically reviewed by Amber Patel, MD. Nouri content is reviewed by licensed clinicians and updated as guidance changes.

Is there an established BPC 157 dosage?

Short version: no. The honest starting point is that there is no legitimate BPC 157 dosage to give you — and understanding why is more useful than any figure on a forum. BPC-157 has never been through the human dose-finding trials that produce a real prescribing range. There is no FDA-approved product, so there is no approved strength, no approved schedule, and no regulated manufacturer standing behind what is in the vial. The NIH NCATS drug record for BPC-157 lists it as an unapproved substance. A "dose" only means something when there is a characterized product and validated human data behind it, and here there is neither.

That is why this article does not walk you through reconstitution, syringe units, or a weekly schedule. Those steps imply a safe, known quantity exists. It doesn't. What the literature offers instead is a set of conventions — figures borrowed from animal experiments and repeated in clinic protocols — that describe what some people have done, not what has been shown safe or effective in humans.

Why is self-dosing gray-market BPC 157 dangerous?

This is the part that matters most, so it comes before any numbers. When you buy BPC-157 from a research-chemical vendor and inject it, you have no reliable way to know what is actually in the vial — and the data on that are alarming.

The clearest evidence comes from a peer-reviewed 2024 analysis in JMIR that tested injectable peptide products (semaglutide) sold online by sellers without a prescription — the same channel that markets BPC-157. It found bacterial endotoxin in 100% of samples, measured active-ingredient purity of just 7.7% to 14.37% against a claimed 99%, and reported that roughly 59-64% of products failed basic visual quality criteria. Separate independent testing of research peptides has found the wrong amino-acid sequence in about 30% of samples — meaning the vial may not even contain the molecule on the label. Add heavy-metal contamination, and the picture is of a product category you cannot dose safely because you cannot trust the contents.

People often wave this away with a certificate showing "99% purity." Here is the catch, and it is the core reason a tested, licensed channel matters: a purity test checks identity, not sterility or endotoxin. It tells you the molecule roughly matches the label. It does not tell you the vial is free of the bacterial endotoxin that the JMIR analysis found in every sample. A vial can be pure on paper and still make you sick when injected, because endotoxin survives the purification steps that a purity assay measures.

There is also the time dimension. Even setting contamination aside, there is no established human safety data for BPC-157 beyond roughly 12 weeks, and its long-term immunogenicity — whether repeated injection provokes an immune response — has not been assessed. So "how much, how often, for how long" has no evidence-based answer.

What did the research literature report for BPC 157 dosage?

With all of that context in place, here is what the literature and clinic protocols have reported — presented as convention, not instruction. Most preclinical BPC-157 work has been done in rats, where the peptide showed effects on wound, tendon, and muscle healing via angiogenesis in the 2021 Frontiers in Pharmacology review, and on gut and brain-gut pathways in Current Neuropharmacology and Pharmaceuticals. These are animal findings; none establishes a human benefit or a human dose.

Translated into the figures that circulate in clinic protocols and online, the commonly cited range is roughly 200-500 mcg per day given subcutaneously, sometimes up to about 1,000 mcg, often injected near the site of injury and run in 4-6 week cycles. A neutral evidence review at Examine.com reaches the same bottom line: high apparent efficacy in rats, very little human evidence. It is worth being explicit about where those numbers come from and what they are not.

Reported figure	What it actually is
~200-500 mcg/day subcutaneous (up to ~1,000)	A convention drawn from animal-equivalent scaling and clinic practice — not an FDA-established dose or a trial-validated range.
Injected "near the injury"	A protocol habit reflecting animal wound-healing models — not a proven route or placement in humans.
4-6 week cycles	A usage convention, not a safety-tested duration; no human safety data exist beyond ~12 weeks.
"99% purity" certificate	An identity check only — it does not measure sterility or endotoxin, which was present in 100% of JMIR-tested samples.

Every row in that table is a caveat. These are not doses in the medical sense. The first rigorous registered human trial of BPC-157 — a Phase 2 study for acute hamstring strain — is only now recruiting and has produced no results. Until studies like it report, there is no validated human dose to hand anyone, which is precisely why no responsible source should be giving you an injection schedule.

What is the FDA status of BPC 157?

BPC-157 is not FDA-approved and is not on the 503A Bulks List, which means there is no legal pathway to compound or sell it today. The FDA placed BPC-157 into 503A "Category 2" — substances that may present a significant safety risk — in 2023.

At the FDA's Pharmacy Compounding Advisory Committee meeting on July 23-24, 2026 (docket FDA-2025-N-6895, announced in the Federal Register), BPC-157 was among the peptides reviewed, and FDA staff proposed that these peptides not be added to the compounding list — citing that they are poorly characterized, with little human efficacy evidence and insufficient safety data including unassessed immunogenicity. Two points of precision matter: that committee is advisory and non-binding, and any final rule would require formal notice-and-comment rulemaking. So the accurate framing is "FDA staff proposed not to list it," not "the FDA banned it." Either way, the practical reality for a consumer is the same — there is no legitimate, tested channel to obtain a properly dosed BPC-157 product today.

How does BPC 157 dosing compare to what a legitimate channel looks like?

Dosing is a dead end for BPC-157 because it only works inside a legitimate supply chain — a characterized product, a known concentration, sterility and endotoxin testing, a prescriber, and a manufacturer accountable for the vial. None of that exists for peptides sold by research-chemical vendors, which is exactly what the JMIR contamination data reflect.

Nouri does not sell BPC-157 or any peptide, and there is no approved product to offer. What we can do is be straight about where the science and the regulations actually stand — and let you be first to know if and when licensed, tested peptide options ever become available through a legitimate, prescribed channel. If that matters to you, you can join the Nouri peptide waitlist. It is not a preorder and implies no availability date; it is simply a way to be notified if the regulatory picture changes.

To go deeper on the peptide itself, start with our pillar explainer, what BPC-157 is and what the science shows. If you are weighing whether to use it at all, read our breakdown of BPC-157 side effects and gray-market safety risks and an honest look at what BPC-157 benefits the research is and isn't showing. If you have seen it stacked with another peptide, we cover that in BPC-157 and TB-500 combined.

Frequently asked questions

Is there an FDA-approved BPC 157 dosage? No. BPC-157 is not FDA-approved and is not on the 503A Bulks List, so there is no approved product and no FDA-established dose. The figures circulated online come from animal studies and clinic protocol conventions, not from validated human dosing trials.

What dose of BPC 157 did the research report? Preclinical studies and clinic protocols have reported roughly 200-500 mcg per day subcutaneously, sometimes up to about 1,000 mcg, often near the site of injury and run in 4-6 week cycles. These are conventions and animal-equivalent figures, not proven human doses. The first rigorous registered human trial is only now recruiting.

Why is self-dosing gray-market BPC 157 dangerous? Because you cannot verify the contents. A 2024 JMIR analysis found endotoxin in 100% of tested products and purity of 7.7-14.37% against a claimed 99%. Independent testing has also found the wrong amino-acid sequence in about 30% of research peptides. Heavy-metal contamination, unassessed immunogenicity, and no established human safety beyond ~12 weeks compound the risk.

Does a "99% pure" label make BPC 157 safe to dose? No. A purity certificate tests identity, not sterility or endotoxin. A vial can read 99% pure and still carry the bacterial endotoxin that the 2024 JMIR analysis found in every sample. Purity on paper is not the same as safe to inject.

Can a doctor legally prescribe or compound BPC 157? Not today. BPC-157 is not on the 503A Bulks List and was placed in Category 2 in 2023, so there is no legal compounding pathway. At the July 2026 advisory review, FDA staff proposed it not be listed. That committee is advisory and non-binding, and any final rule would require notice-and-comment rulemaking.

How long is BPC 157 considered safe to take? There is no established human safety window. Protocol figures describe 4-6 week cycles, but that is convention rather than evidence, and no human safety data exist beyond roughly 12 weeks. Long-term immunogenicity has not been assessed.

Sources & data

Primary and secondary sources cited above:

• Multifactor Quality and Safety Analysis of Semaglutide Products Sold by Online Sellers Without a Prescription — JMIR, 2024 (endotoxin in 100% of samples; purity 7.7-14.37% vs 99% claimed). The study analyzed unprescribed injectable peptide products of the type the gray market also sells as BPC-157.
• Stable Gastric Pentadecapeptide BPC 157 and Wound Healing — Frontiers in Pharmacology, 2021 (animal healing data; absence of human trials acknowledged).
• BPC 157: Angiogenesis and the NO-System — Pharmaceuticals (Basel), 2025 (proposed mechanism; human data limited).
• Brain-gut Axis and Pentadecapeptide BPC 157 — Current Neuropharmacology, 2016 (preclinical).
• BPC 157 for Acute Hamstring Muscle Strain Repair (NCT07437547) — ClinicalTrials.gov (Phase 2, recruiting; no results).
• BPC-157 — NIH NCATS Inxight Drugs record (identity and unapproved-drug status).
• Pharmacy Compounding Advisory Committee Notice of Meeting — Federal Register (July 23-24, 2026 review; docket FDA-2025-N-6895).
• BPC-157 — Examine.com (neutral evidence review: strong in rats, little human evidence).

This article is educational and is not medical advice. BPC-157 is not FDA-approved, has no validated human dose, and has no legal compounding or sales pathway at this time. Do not attempt to source or self-inject peptides from unregulated vendors.

Want to be notified if licensed, tested peptide options ever become available? Join the Nouri peptide waitlist — no preorder, no obligation, just first notice if the regulatory picture changes. If you came here exploring a medically supervised path to a health goal like weight management instead, you can also learn about the Nouri program.